Nov 05, 2021 11:02 AM IST

Buy Sun Pharmaceutical Industries; target of Rs 965: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 965 in its research report dated November 03, 2021.

Sun Pharma Standalone September 2021 Net Sales at Rs 4,143.15 crore, up 25.84% Y-o-Y

Sun Pharma Consolidated September 2021 Net Sales at Rs 9,625.93 crore, up 12.54% Y-o-Y

Sun Pharma: Buy, sell or hold? What should investors do after Q2 results?

Sun Pharma’s consolidated revenue came in higher at Rs 9,626 crore for the quarter, compared to Rs 8,553 crore in September 2020 quarter, registering a 12.5 percent growth.

Sun Pharma Q2 Results | Profit rises 13% to Rs 2,047 crore, revenue grows 12.5%

Sun Pharma Q2 Results | The sequential growth in profit and revenue was 41.8 percent and (-1) percent respectively.

Sun Pharma launches acne treatment cream Winlevi in US market

A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (FDA) in August 2020.

Sun Pharmaceutical Industries Q2 PAT seen up 15.6% YoY to Rs 2,094.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 13.3 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs 9,584.3 crore, according to Prabhudas Lilladher.

Hot Stocks: 'Can bet on Sun Pharma, BHEL and Canara Bank for double-digit returns in 2-3 weeks'

The key support levels to watch for in the short term are 17,531 (20-Day SMA) and 17,254 (3-Week Low), said Vidnyan Sawant of GEPL Capital,

Hot Stocks | Here's why you should buy Sun Pharma & Dixon Tech, but sell Britannia futures

As Nifty is still trading within the rising channel pattern, the bullish trend is most likely to continue, going ahead, says Rohan Patil of Bonanza Portfolio.

Sun Pharma Consolidated June 2021 Net Sales at Rs 9,718.74 crore, up 28.13% Y-o-Y

Sun Pharma Standalone June 2021 Net Sales at Rs 3,325.95 crore, up 12.25% Y-o-Y

Buy Sun Pharmaceutical Industries: target of Rs 900: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 900 in its research report dated July 30, 2021.

What should investors do with Sun Pharma post Q1 results: buy, sell or hold?

Sun Pharma Q1 results: Motilal Oswal is positive on the company due to - investments in the global Specialty portfolio improving overall profitability, robust pipeline of NDAs/ANDAs, and revival in the Branded Generics segment

Sun Pharma posts Rs 1,444.17-crore net profit in June quarter

The company had posted a net loss of Rs 1,655.60 crore for the corresponding period of the previous fiscal, Sun Pharma said in a regulatory filing.

Sun Pharma share price locked in 10% upper circuit on turning profitable in Q1FY22

Sun Pharma has reported a net profit of Rs 1,444.1 crore in the quarter ended Q1FY22 against a loss of Rs 1,655.6 crore in the year-ago period

Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey

Net Sales are expected to increase by 12.7 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs 8,547.7 crore, according to KRChoksey.

Buy Sun Pharmaceutical Industries; target of Rs 783: Geojit

Geojit is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 783 in its research report dated June 02, 2021.

Hold Sun Pharmaceutical Industries; target of Rs 700: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 700 in its research report dated May 28, 2021.

Buy Sun Pharmaceutical Industries: target of Rs 810: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 810 in its research report dated May 27, 2021.

Sun Pharma Consolidated March 2021 Net Sales at Rs 8,522.98 crore, up 4.13% Y-o-Y

Sun Pharma Standalone March 2021 Net Sales at Rs 3,159.64 crore, up 11.41% Y-o-Y

What should investors do with Sun Pharma post Q4 earnings: buy, sell or hold?

Here is what brokerages have to say about the stock and the company after the March quarter earnings announcement:

Sun Pharma Q4 net profit zooms over two-fold to Rs 894.15 crore

For the full fiscal 2020-21, the company posted a net profit of Rs 2,903.82 crore as against Rs 3,764.93 crore in the previous financial year.

Sun Pharma to announce Q4 results today; here what brokerages expect

The pharma major is likely to report a more than 100 percent year-on-year growth in profit, backed by healthy operating performance, and low base in the year-ago quarter.

Buy Sun Pharmaceutical Industries: target of Rs 700: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 700 in its research report dated April 01, 2021.